Physician profile
Stephen John Chu
NPI 1992917983
$477,281.53
in general payments reported to CMS, 2019-2025
11 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Prosthodontics providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $22K · 2021: $52K · 2022: $85K · 2023: $13K · 2024: $141K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Education: $70K · Royalty Or License: $67K · Travel and Lodging: $24K · Honoraria: $15K · Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $99,595.00 |
| Education | $70,151.67 |
| Royalty Or License | $67,146.02 |
| Travel and Lodging | $24,219.43 |
| Honoraria | $15,000.00 |
| Food and Beverage | $1,661.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Southern Implants North America INC | $268,203.37 | 2019-2025 | Inverta |
| Zimvie INC. | $108,979.21 | 2022-2025 | |
| Hu-Friedy Mfg. Co., LLC | $82,298.87 | 2019-2025 | Hu-Friedy Mfg. Co., LLC |
| Envista Holdings Corporation | $15,640.94 | 2024 | Education |
| Kulzer, LLC | $1,500.00 | 2019 | |
| Ivoclar Vivadent, INC. | $280.60 | 2023 | |
| Biohorizons Implant Systems INC. | $157.56 | 2019-2021 | |
| Ormco Corporation | $79.11 | 2021 | |
| Nobel Biocare USA | $78.05 | 2022 | |
| Neoss, INC. | $33.95 | 2024 | Neoss Implant System |
| Keystone Dental INC. | $29.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.